
TVRD Stock Forecast & Price Target
TVRD Analyst Ratings
Bulls say
Tvardi Therapeutics is expected to have a positive outlook, with potential for improved tolerability and convenience with their second-generation STAT3 inhibitor, TTI-109, compared to TTI-101. The company has multiple opportunities for pipeline expansion and therapeutic relevance, particularly in the areas of fibrosis and cancer, with topline results for the Phase 1b/2 trial in hepatocellular carcinoma expected to be a key catalyst in the second half of 2026. Additionally, strong financials and ample cash reserves provide confidence in the company's ability to fund operations and future development plans.
Bears say
Tvardi Therapeutics is leveraging its specialized focus on the development of small molecule therapies targeting STAT3 to potentially treat fibrosis-driven diseases. With a unique approach to blocking STAT3, the company's lead program, TTI-101, has shown early promise in advanced tumors and is currently undergoing clinical trials in hepatocellular carcinoma. Additionally, TTI-109, the prodrug form of TTI-101, may offer improved tolerability and a wider therapeutic window, making it a potential candidate for future development.
This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TVRD Analyst Forecast & Price Prediction
Start investing in TVRD
Order type
Buy in
Order amount
Est. shares
0 shares